The prognostic value of alpha-thymosins in breast cancer
- PMID: 9673361
The prognostic value of alpha-thymosins in breast cancer
Abstract
The prognosis of breast cancer is of major clinical importance and several histopathological, biochemical and immunological variables have been reported to be useful prognostic factors. In the present study, we investigated the clinical significance of the levels of alpha-thymosins in relation to established prognostic factors, both in breast cancer and non-malignant breast lesions, alpha-thymosin levels were measured in breast tissue extracts by specific radioimmunoassays (RIAs) developed for human prothymosin alpha (ProT alpha) and parathymosin alpha (ParaT alpha) and were found to be significantly higher (up to 17.2-fold) in malignant but not in benign breast lesions, as compared to the values of the neighbouring tissues. When alpha-thymosin levels of the tumor samples were correlated with various known prognostic parameters a statistically significant correlation (p < 0.05) was observed between the levels of ProT alpha in malignant tissues to the grade of cancer and the lymph node status of the patient. An association between ProT alpha levels with increase in risk of death from breast cancer was also noticed. These results suggest that the expression of alpha-thymosins in human breast cancer a) depends on the proliferation status of the tumor, b) associates with established prognostic factors describing the metastatic potential of the tumor and c) is related to the overall survival of the patient. The fact that such relationships hold only for cancer tissues encourages the future use of alpha-thymosins as potent prognostic factors in breast cancer.
Similar articles
-
Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma.Clin Cancer Res. 1998 Mar;4(3):671-6. Clin Cancer Res. 1998. PMID: 9533536
-
Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.Anticancer Res. 1999 Jul-Aug;19(4A):2557-62. Anticancer Res. 1999. PMID: 10470194
-
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.Anticancer Res. 2006 Nov-Dec;26(6C):4985-90. Anticancer Res. 2006. PMID: 17214375
-
[Prognostic factors in breast cancer].Gynakologe. 1994 Feb;27(1):37-44. Gynakologe. 1994. PMID: 8168736 Review. German. No abstract available.
-
["Prognostic factors" in breast cancer--1].Z Arztl Fortbild (Jena). 1994 Feb;88(2):111-4. Z Arztl Fortbild (Jena). 1994. PMID: 8147017 Review. German. No abstract available.
Cited by
-
Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity.Mol Cell Biol. 2000 Sep;20(17):6224-32. doi: 10.1128/MCB.20.17.6224-6232.2000. Mol Cell Biol. 2000. PMID: 10938099 Free PMC article.
-
Identification of common microRNA-mRNA regulatory biomodules in human epithelial cancers.Chin Sci Bull. 2010 Nov;55(31):3576-3589. doi: 10.1007/s11434-010-4051-1. Chin Sci Bull. 2010. PMID: 21340045 Free PMC article.
-
Roles of thymosins in cancers and other organ systems.World J Surg. 2005 Mar;29(3):264-70. doi: 10.1007/s00268-004-7817-2. World J Surg. 2005. PMID: 15706436 Review.
-
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitam Horm. 2016;102:179-207. doi: 10.1016/bs.vh.2016.04.008. Epub 2016 May 27. Vitam Horm. 2016. PMID: 27450735 Free PMC article. Review.
-
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.Cancer Immunol Immunother. 2012 May;61(5):599-614. doi: 10.1007/s00262-012-1222-8. Epub 2012 Feb 26. Cancer Immunol Immunother. 2012. PMID: 22366887 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical